Therapeutic | Zolimomab |
Target | CD3E |
Heavy Chain | QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS |
Light Chain | QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIN |
100% seqID Fv Structure | 1sy6 [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 1sy6 [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2a |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 1988 |
INN Year Recommended | 1989 |
Companies Involved | Cancer Research UK, Ortho-McNeil, XOMA |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Diabetes mellitus, Graft-versus-host disease, Renal transplant rejection, Rheumatoid arthritis |
Notes | Muromonab and Zolimomab are the same mAb. LC IMGT 127 is N not K as in Jain paper. |